TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16266300

Group type: EXPERIMENTAL
Intervention: End-point rectal rewarming temperature at 35.5 degrees C (Group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: End-point rectal rewarming temperature at 37.0 degrees C (Group 2)
Number of subjects: 50
Study: 11867825

Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 44
Study: 10195545

Group type: EXPERIMENTAL
Intervention: Size 4 LMA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Size 4 FLMA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Size 5 LMA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Size 5 FLMA
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: LMA groups combined
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: LMA groups
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: LMA groups vs Control group
Number of subjects: 50
Study: 7849875

Group type: EXPERIMENTAL
Intervention: Prenatal marijuana exposure
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 2183942

Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg daily during RT)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg daily after RT)
Number of subjects: 89
Study: 7426142

Group type: EXPERIMENTAL
Intervention: Propranolol 0.1 mg/kg intravenously followed by 320 mg in divided doses over 27 hours orally
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (29 patients)
Number of subjects: 62
Study: 31156210

Group type: EXPERIMENTAL
Intervention: Sleep posture recording protocol using infrared cameras under various light and bed cover situations.
Number of subjects: 20
Study: 29245871

Group type: EXPERIMENTAL
Intervention: Frequency-entangled state
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dichromatic path‐entangled state
Number of subjects: 0
Study: 25886200

Group type: EXPERIMENTAL
Intervention: Welfare-to-work schemes combined with alcohol treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Welfare-to-work schemes alone
Number of subjects: 0
Study: 23507858

Group type: EXPERIMENTAL
Intervention: Photoselective vaporization of the prostate (PVP) with GreenLight HPS laser
Number of subjects: 200

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 200
Study: 21838823

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tracheal Tube (TT)
Number of subjects: 30
Study: 19628959

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Rogerian supportive therapy (RST)
Number of subjects: 65
Study: 18614890

Group type: EXPERIMENTAL
Intervention: Aerobic exercise group (n = 15) participated in a 6-week, twice-weekly indoor exercise program (45 minutes of gymnastics with music and 15 minutes of progressive muscle relaxation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aerobic exercise group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (standard medical care)
Number of subjects: 30
Study: 15468140

Group type: EXPERIMENTAL
Intervention: Scyllo-inositol measurement in older subjects
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Myo-inositol measurement in older subjects
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Test-retest studies on scyllo-inositol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Test-retest studies on N-acetyl aspartate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Correlation between scyllo-inositol and myo-inositol levels
Number of subjects: 24
Study: 11867375

Group type: EXPERIMENTAL
Intervention: Desflurane (3%-6% end tidal) with nitrous oxide 70% in oxygen
Number of subjects: 90

Group type: COMPARATOR
Intervention: Isoflurane (0.7%-1.2% end tidal) with nitrous oxide 70% in oxygen
Number of subjects: 90

Group type: COMPARATOR
Intervention: Propofol (75-150 microg kg(‐1) min(‐1) IV) with nitrous oxide 70% in oxygen
Number of subjects: 90
Study: 10448260

Group type: EXPERIMENTAL
Intervention: Glycyl‐L‐glutamine supplementation
Number of subjects: 24

Group type: COMPARATOR
Intervention: No glutamine supplementation (control)
Number of subjects: 24
Study: 7603726

Group type: EXPERIMENTAL
Intervention: Vestibular adaptation exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 2182891

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Observation without therapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: High expression of Ki-67, absence of CD9 and CD10, and blastic morphology
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Liver involvement documented by biopsy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Complete responses lasting longer than 2 years
Number of subjects: 23
Study: 7010382

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 29112827

Group type: EXPERIMENTAL
Intervention: Average grams per cannabis administration
Number of subjects: 300
Study: 27236654

Group type: EXPERIMENTAL
Intervention: Increased LV threshold group
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: hs-CRP increase
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 1,25 (OH)2 vitamin D decrease
Number of subjects: 200
Study: 25056602

Group type: EXPERIMENTAL
Intervention: Group A (60 gray in 27 fractions)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Group B (68 gray in 34 fractions)
Number of subjects: 117
Study: 21617973

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (Laser Smile™, Biolase®, San Clemente, USA) applied to the wound after surgery with 5 J/cm² energy density, 810 nm wavelength, and 0.5 W output power.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control side (placebo) where a handpiece was applied but the laser was not activated.
Number of subjects: 20
Study: 20370946

Group type: EXPERIMENTAL
Intervention: Test chocolate with maltitol (MTL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Test chocolate with MTL and polydextrose (PDX)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Test chocolate with MTL and PDX
Number of subjects: 40
Study: 18564999

Group type: EXPERIMENTAL
Intervention: Topical 5% liposomal lidocaine cream
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 18
Study: 16602203

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa)
Number of subjects: 0
Study: 12888150

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated subjects with combined hyperlipidemia
Number of subjects: 0
Study: 10084567

Group type: EXPERIMENTAL
Intervention: 40 mg isoflavones from red clover
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 80 mg isoflavones from red clover
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 7795355

Group type: EXPERIMENTAL
Intervention: Abbreviated pediatric odorant identification task (sniffing and identifying five odorants: baby powder, bubble gum, candy cane, licorice, peach)
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Abbreviated pediatric odorant identification task
Number of subjects: 825

Group type: COMPARATOR
Intervention: Adult subjects with olfactory dysfunction
Number of subjects: 825
Study: 1881295

Group type: EXPERIMENTAL
Intervention: Ethnomedicine (specific intervention details not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies (case series)
Number of subjects: 0
Study: 6776833

Group type: EXPERIMENTAL
Intervention: Intermittent positive pressure breathing
Number of subjects: 17

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 17
Study: 31338563

Group type: EXPERIMENTAL
Intervention: Vitamin D, calcium and leucine-enriched whey protein drink (2/day)
Number of subjects: 380
Study: 28168201

Group type: EXPERIMENTAL
Intervention: 12-week group-based lifestyle intervention program (n = 34)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group receiving standard print material on diabetes prevention (n = 36)
Number of subjects: 70
Study: 25466315

Group type: EXPERIMENTAL
Intervention: Humalog insulin (Hlog)
Number of subjects: 28
Study: 23354552

Group type: EXPERIMENTAL
Intervention: Oral palonosetron 0.25 mg
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Oral palonosetron 0.50 mg
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Oral palonosetron 0.75 mg
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: IV palonosetron 0.25 mg
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg IV
Number of subjects: 651

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 651
Study: 21034692

Group type: EXPERIMENTAL
Intervention: Levetiracetam (up to 2,500 mg/d flexibly dosed)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 42
Study: 19026570

Group type: EXPERIMENTAL
Intervention: Disc A (auditory information during anesthesia)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Disc B (auditory information during anesthesia)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No auditory information (not heard during anesthesia) for Disc A
Number of subjects: 38

Group type: COMPARATOR
Intervention: No auditory information (not heard during anesthesia) for Disc B
Number of subjects: 38
Study: 17085269

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention directed toward both the patient and family caregivers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional care alone
Number of subjects: 0
Study: 14979621

Group type: EXPERIMENTAL
Intervention: Doxazosin as add-on therapy
Number of subjects: 561
Study: 11337538

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg oral amphetamine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9398701

Group type: EXPERIMENTAL
Intervention: GH and LH‐releasing hormone (LHRH) analog
Number of subjects: 14

Group type: COMPARATOR
Intervention: GH and placebo
Number of subjects: 14
Study: 7956639

Group type: EXPERIMENTAL
Intervention: Nicotinamide (NCT) plus deflazacort (DFL) for 3 months (25 mg.kg-1.day-1 for NCT, 0.6 mg.kg-1.day-1 for DFL in the first month, 0.3 mg.kg-1.day-1 for DFL in the other 2 months)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nicotinamide (NCT) plus deflazacort (DFL)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nicotinamide (NCT) plus placebo
Number of subjects: 36
Study: 3316240

Group type: EXPERIMENTAL
Intervention: Cefuroxime administered 10 minutes before tourniquet inflation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefuroxime administered at various intervals before tourniquet inflation
Number of subjects: 0
Study: 31657454

Group type: EXPERIMENTAL
Intervention: Rituximab + short-term prednisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard corticosteroid regimen (prednisone alone)
Number of subjects: 0
Study: 30784669

Group type: EXPERIMENTAL
Intervention: Full post-PCI bivalirudin infusion (1.75 mg/kg/h for ≤4 h)
Number of subjects: 3610

Group type: COMPARATOR
Intervention: Low post-PCI bivalirudin infusion (0.25 mg/kg/h for ≤6 h)
Number of subjects: 3610

Group type: COMPARATOR
Intervention: No post-PCI bivalirudin infusion or heparin
Number of subjects: 3610
Study: 28642308

Group type: EXPERIMENTAL
Intervention: Risk score containing age, smoking status, dyspnoea, prescriptions of salbutamol and prescriptions of antibiotics
Number of subjects: 2398

Group type: EXPERIMENTAL
Intervention: Cut-point of ≥7.5% predicted risk
Number of subjects: 2398
Study: 25197733

Group type: EXPERIMENTAL
Intervention: Chocobar ice cream with probiotics
Number of subjects: 30

Group type: COMPARATOR
Intervention: Chocobar ice cream without probiotics
Number of subjects: 30
Study: 23551727

Group type: EXPERIMENTAL
Intervention: Nebivolol (5-40 mg/d)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ; 12.5-25 mg/d)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 537
Study: 21528169

Group type: EXPERIMENTAL
Intervention: Consumption of soft plain cheese (fortified with vitamin D3 and calcium)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control period (6 weeks without soft plain cheese consumption)
Number of subjects: 29
Study: 18037478

Group type: COMPARATOR
Intervention: CT/RT
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: CT/RT+R‐HUEPO
Number of subjects: 109
Study: 17060297

Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 15262457

Group type: EXPERIMENTAL
Intervention: Fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cinnarizine 20 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dimenhydrinate 40 mg
Number of subjects: 50
Study: 11200658

Group type: EXPERIMENTAL
Intervention: Acetyl starch (ACS)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Hydroxyethyl starch (HES)
Number of subjects: 17
Study: 9257073

Group type: EXPERIMENTAL
Intervention: New antithrombotic drug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8483109

Group type: EXPERIMENTAL
Intervention: Zidovudine, 200 mg orally every 4 hours (1,200 mg daily)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 2450237

Group type: EXPERIMENTAL
Intervention: Carteolol (nonselective beta‐adrenoceptor blocker)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Carteolol
Number of subjects: 8
Study: 28153503

Group type: EXPERIMENTAL
Intervention: Whey protein mixture with added tryptophan (TRP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Whey protein only (control)
Number of subjects: 32
Study: 27518195

Group type: EXPERIMENTAL
Intervention: 40-mg intravenous omeprazole (OME) bolus injection every 12 hours
Number of subjects: 41

Group type: COMPARATOR
Intervention: 8-mg/h continuous intravenous infusion of omeprazole (OME) for 72 hours after an 80-mg i.v. OME bolus administration
Number of subjects: 41

Group type: COMPARATOR
Intervention: 8-mg/h continuous intravenous infusion of omeprazole (OME) for 72 hours
Number of subjects: 41
Study: 24548278

Group type: EXPERIMENTAL
Intervention: Cypher™ stent
Number of subjects: 2098

Group type: COMPARATOR
Intervention: Taxus™ stent
Number of subjects: 2098
Study: 23406757

Group type: COMPARATOR
Intervention: Enalapril (20 mg daily)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg daily)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 20042452

Group type: EXPERIMENTAL
Intervention: Seawater gel nasal spray for 10 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Seawater gel
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 100
Study: 18981767

Group type: EXPERIMENTAL
Intervention: Staggered interruption of NNRTI
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Switched interruption of NNRTI
Number of subjects: 688

Group type: COMPARATOR
Intervention: Simultaneous interruption of NNRTI
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Patients with detectable mutations
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Patients without detectable mutations
Number of subjects: 688
Study: 15755765

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin per day
Number of subjects: 10001

Group type: COMPARATOR
Intervention: 10 mg atorvastatin per day
Number of subjects: 10001
Study: 12868251

Group type: EXPERIMENTAL
Intervention: Daily exposure to a small, portable pulsing electromagnetic field generator
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 117
Study: 11825313

Group type: EXPERIMENTAL
Intervention: Anti-oxidant therapy (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin E (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural and synthetic anti-oxidants (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary intake of natural anti-oxidant vitamins (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surrogate markers of CVD (specifics not provided)
Number of subjects: 0
Study: 9148349

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg intravenous)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7936855

Group type: COMPARATOR
Intervention: Vitamin D alone for 5.36 ± 2.18 years
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Vitamin D and phosphate therapy for 4.33 ± 2.19 years
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vitamin D alone vs Vitamin D and phosphate therapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Vitamin D and phosphate therapy added to Vitamin D alone
Number of subjects: 36
Study: 3361212

Group type: EXPERIMENTAL
Intervention: Supportive bandage
Number of subjects: 108

Group type: COMPARATOR
Intervention: Dorsal plaster cast
Number of subjects: 108
Study: 31021311

Group type: EXPERIMENTAL
Intervention: Single-puncture arthrocentesis
Number of subjects: 32

Group type: COMPARATOR
Intervention: Double-puncture arthrocentesis
Number of subjects: 32
Study: 31957726

Group type: EXPERIMENTAL
Intervention: Training program on primary eye care (PEC) for ASHAs, one day training duration.
Number of subjects: 0
Study: 28899995

Group type: EXPERIMENTAL
Intervention: Mobile van testing for HIV
Number of subjects: 8756
Study: 26908741

Group type: EXPERIMENTAL
Intervention: ogp160 MN/LAI-2 with polyphosphazene (pP)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: ogp160 MN/LAI-2 with alum
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP205) with ogp160 MN/LAI-2
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: ogp160 protein alone
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: prime-boost regimen (ALVAC-HIV and ogp160)
Number of subjects: 91

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 91
Study: 25304863

Group type: EXPERIMENTAL
Intervention: 20 mg oral cortisol
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 23855759

Group type: EXPERIMENTAL
Intervention: BIS-guided TIVA with propofol and remifentanil
Number of subjects: 157

Group type: COMPARATOR
Intervention: Conventional clinical practice TIVA with propofol and remifentanil
Number of subjects: 157
Study: 20304608

Group type: EXPERIMENTAL
Intervention: Embedded HIPAA authorization form in the survey
Number of subjects: 1099

Group type: COMPARATOR
Intervention: HIPAA form requiring signature for consent sent after the survey
Number of subjects: 1099

Group type: COMPARATOR
Intervention: HIPAA form requiring signature and SSN for consent sent after the survey
Number of subjects: 1099
Study: 18823299

Group type: EXPERIMENTAL
Intervention: etoricoxib 120 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 16364517

Group type: EXPERIMENTAL
Intervention: Maximum flexion with 20 kg load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum lateral bending with 20 kg load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum flexion and lateral bending with 20 kg load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various postures and loading conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stretched muscle under loading conditions
Number of subjects: 0
Study: 14529095

Group type: EXPERIMENTAL
Intervention: Swimming lesson group (5- to 6-week session)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8
Study: 10944597

Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) at 200 mg/m(2)/day or 150 mg/m(2)/day for 5 days, repeated every 28 days
Number of subjects: 225

Group type: COMPARATOR
Intervention: Procarbazine (PCB) at 150 mg/m(2)/day or 125 mg/m(2)/day for 28 days, repeated every 56 days
Number of subjects: 225
Study: 9005369

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 65
Study: 1728819

Group type: EXPERIMENTAL
Intervention: Test blends of edible oils with PMS ratio of approximately 0.8:1.3:1
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control dietary periods resembling Australian fat intake with PMS ratio of 0.4:0.9:1
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Test blends of edible oils with 16% trans fatty acid content
Number of subjects: 26
Study: 30590861

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention based on the Theory of Triadic Influence (TTI) including a 50 min motivational interview and online self-help material, with follow-up support via email and group therapy.
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control group (n = 122)
Number of subjects: 255
Study: 28394521

Group type: EXPERIMENTAL
Intervention: Low dose-rate brachytherapy using domestically manufactured I-125 seeds with a minimum therapeutic dose of 145 Gy, average of 57 seeds implanted (0.55 and 0.35 mCi per seed).
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Brachytherapy combined with laparoscopic pelvic lymphadenectomy for intermediate risk group patients.
Number of subjects: 36
Study: 26835147

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (CYC) 0.5-1 g/m² monthly for first 6 months, then EC-MPS 720 mg/day until 12 months
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) 1440 mg/day for first 6 months, then EC-MPS 720 mg/day until 12 months
Number of subjects: 59
Study: 25132803

Group type: EXPERIMENTAL
Intervention: Pharmacological preconditioning with sevoflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Number of subjects: 40
Study: 22314029

Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 260
Study: 20109120

Group type: EXPERIMENTAL
Intervention: Ultra absorbency tampon (15 g to 18 g)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Super-plus absorbency tampon (12 g to 15 g)
Number of subjects: 95